Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Looking for Catalysts for China Equity Rebound

BY | ETF Database
04/04/2024 | 189 VIEWS
  • Related Symbols
  • KBA
China stocks and related ETFs remain sources of consternation for investors. Yet some experts believe now isn’t the time to ignore the asset class. The key is identifying the right ways to access the country’s stocks in an effort to position for a potential rebound.Take the case of the KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA A-). The fund is higher by nearly 5% year to date, while the MSCI China Index is saddled with a small loss. Acknowledging that gap, it’s possible that, should more global investors see opportunity with Chinese stocks, KBA could emerge as a leader among U.S.-listed China ETFs. There are already signs that rebound could be forming. The MSCI China Index well off its January lows. But KBA is higher by 3.53% over the past month. Those could be signs some institutional buyers are nibbling at Chinese stocks.KBA Could Be Credible Rebound CandidateIntegral to the China equity thesis are the country’s economic data and the point that stocks there are inexpensive. However, many market participants won’t embrace the latter without support from the former. Fortunately, that scenario could be improving. “China’s stocks are flat so far in 2024 and valuations are in line with 20-year lows,” noted Jeffrey Kleintop of Charles Schwab. “There have been some green shoots, with better-than-expected export growth in the combined January-February data, supported by the global manufacturing recovery we believe has started.” Still, China has a confidence problem. Shaking free of low consumer, corporate, and investor confidence could be what’s needed to propel stocks there higher. Much of that lack of esteem is attributable to long-running issues in the country’s property and lack of bold response by the central bank. One avenue to restore confidence would be for Beijing to loosen capital controls. Global investors have worried about the government’s regulatory efforts over the past several years, including restrictions on capital. Regulations are seen as hindering foreign investment and innovation in China. That confirms that if those policies are altered, KBA could respond in positive fashion. “There are no signs of any major imminent shift in policy in China. But it is worth keeping in mind that China’s policymakers rarely signal such changes in advance. Any surprises could potentially trigger sharp rebounds in China’s stock market, like in late 2022 when the zero-COVID restrictions were suddenly dropped. China’s stocks shot up 60% over the subsequent three-month period,” concluded Kleintop.For more news, information, and analysis, visit the China Insights Channel.

More Commentary

Position European Funds Ahead of Rate Shifts
BY | ETF Database
04/29/2024 | 16 VIEWS
Earnings Theater Likely Meaningful for These ETFs
BY | ETF Database
04/23/2024 | 162 VIEWS
Top Performing Leveraged/Inverse ETFs: 04/21/2024
BY | ETF Database
04/23/2024 | 757 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.

Copyright 1998–2024 FMR LLC. 
All rights reserved.